“The FDA has made it a priority to help drug developers address the global health crisis posed by multi-drug resistant infections, particularly difficult-to-treat serious and life-threatening Gram-negative infections, through designations like QIDP, which our lead candidate eravacycline was recently awarded,” said Guy Macdonald, Tetraphase President and Chief Executive Officer.